Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.58 |
| ▸ | PLK4 | O00444 | 1/20 | 0.48 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.46 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.45 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.45 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.45 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.45 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.45 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.45 |
| ▸ | GSK3B | P49841 | 3/20 | 0.43 |
| ▸ | APP | P05067 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | SNCA | P37840 | 2/20 | 0.42 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.42 |
| ▸ | RAF1 | P04049 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5366866 | 0.92 | NOX4 (0.58) | NOX4PLK4LRRK2PSEN1PSEN2 | |
| SCHEMBL7136333 | 0.84 | MAPT (0.61) | NOX4PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL7135240 | 0.84 | KDR (0.44) | NOX4LRRK2PSEN1PSEN2APH1B | |
| SCHEMBL7136229 | 0.82 | MAP1LC3B (0.57) | NOX4PLK4LRRK2PSEN1PSEN2 | |
| SCHEMBL5367874 | 0.81 | LRRK2 (0.54) | NOX4PLK4LRRK2PSEN1PSEN2 | |
| SCHEMBL5370082 | 0.81 | LRRK2 (0.70) | NOX4PLK4LRRK2PSEN1PSEN2 | |
| SCHEMBL5357713 | 0.81 | ERBB2 (0.53) | NOX4LRRK2PSEN1PSEN2APH1B | |
| SCHEMBL7133855 | 0.80 | ERBB2 (0.53) | NOX4PLK4LRRK2PSEN1PSEN2 | |
| SCHEMBL5367333 | 0.80 | NOX4 (0.58) | NOX4GSK3BAPPMAPTSNCA | |
| SCHEMBL7133928 | 0.79 | LRRK2 (0.53) | PLK4LRRK2PSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202265-B2 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | FRK, PTK2, DSTYK | NOX4 3452/4885PLK4 42/4885LRRK2 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.